Page 83 - Vitamin D and Cancer

70 A.V. Krishnan and D. Feldman

107. Gasparian AV, Yao YJ, Kowalczyk D, Lyakh LA, Karseladze A, Slaga TJ, Budunova IV
(2002) The role of IKK in constitutive activation of NF-kappaB transcription factor in pros-
tate carcinoma cells. J Cell Sci 115(Pt 1):141–151
108. Ismail HA, Lessard L, Mes-Masson AM, Saad F (2004) Expression of NF-kappaB in pros-
tate cancer lymph node metastases. Prostate 58(3):308–313
109. Suh J, Rabson AB (2004) NF-kappaB activation in human prostate cancer: important media-
tor or epiphenomenon? J Cell Biochem 91(1):100–117
110. Lessard L, Begin LR, Gleave ME, Mes-Masson AM, Saad F (2005) Nuclear localisation of
nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical
study. Br J Cancer 93(9):1019–1023
111. Catz SD, Johnson JL (2001) Transcriptional regulation of bcl-2 by nuclear factor kappa B
and its significance in prostate cancer. Oncogene 20(50):7342–7351
112. Huang S, Pettaway CA, Uehara H, Bucana CD, Fidler IJ (2001) Blockade of NF-kappaB
activity in human prostate cancer cells is associated with suppression of angiogenesis, inva-
sion, and metastasis. Oncogene 20(31):4188–4197
113. Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, Laudone VP, Kreutzer DL
(1998) Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis
factors by prostate cancer cells. Urology 51(1):161–167
114. Yu XP, Bellido T, Manolagas SC (1995) Down-regulation of NF-kappa B protein levels in
activated human lymphocytes by 1, 25-dihydroxyvitamin D3. Proc Natl Acad Sci USA
92(24):10990–10994
115. Harant H, Wolff B, Lindley IJ (1998) 1Alpha, 25-dihydroxyvitamin D3 decreases DNA
binding of nuclear factor-kappaB in human fibroblasts. FEBS Lett 436(3):329–334
116. Stio M, Martinesi M, Bruni S, Treves C, Mathieu C, Verstuyf A, d’Albasio G, Bagnoli S,
Bonanomi AG (2007) The Vitamin D analogue TX 527 blocks NF-kappaB activation in
peripheral blood mononuclear cells of patients with Crohn’s disease. J Steroid Biochem Mol
Biol 103(1):51–60
117. Sun J, Kong J, Duan Y, Szeto FL, Liao A, Madara JL, Li YC (2006) Increased NF-kappaB
activity in fibroblasts lacking the vitamin D receptor. Am J Physiol Endocrinol Metab
291(2):E315–E322
118. Schwab M, Reynders V, Loitsch S, Steinhilber D, Stein J, Schroder O (2007) Involvement of
different nuclear hormone receptors in butyrate-mediated inhibition of inducible NF kappa
B signalling. Mol Immunol 44(15):3625–3632
119. Cohen-Lahav M, Douvdevani A, Chaimovitz C, Shany S (2007) The anti-inflammatory
activity of 1, 25-dihydroxyvitamin D3 in macrophages. J Steroid Biochem Mol Biol
103(3–5):558–562
120. Cohen-Lahav M, Shany S, Tobvin D, Chaimovitz C, Douvdevani A (2006) Vitamin D
decreases NFkappaB activity by increasing IkappaBalpha levels. Nephrol Dial Transplant
21(4):889–897
121. Bao BY, Yao J, Lee YF (2006) 1alpha, 25-dihydroxyvitamin D3 suppresses interleukin-8-
mediated prostate cancer cell angiogenesis. Carcinogenesis 27(9):1883–1893
122. Han J, Jogie-Brahim S, Oh Y (2007). New paradigm foe antitumor action of IGF binding
protein-3 (IGFBP-3): novel NF-kB inhibitory effect of IGFBP-3 in prostate cancer. In:
Proceedings from the Endocrine Society Meeting, Toronto, Canada; pp P3–370
123. Criswell T, Leskov K, Miyamoto S, Luo G, Boothman DA (2003) Transcription factors
activated in mammalian cells after clinically relevant doses of ionizing radiation. Oncogene
22(37):5813–5827
124. Kimura K, Bowen C, Spiegel S, Gelmann EP (1999) Tumor necrosis factor-alpha sensitizes
prostate cancer cells to gamma-irradiation-induced apoptosis. Cancer Res 59(7):1606–1614
125. Xu Y, Fang F, St Clair DK, Josson S, Sompol P, Spasojevic I, St Clair WH (2007) Suppression
of RelB-mediated manganese superoxide dismutase expression reveals a primary mechanism
for radiosensitization effect of 1alpha, 25-dihydroxyvitamin D(3) in prostate cancer cells.
Mol Cancer Ther 6(7):2048–2056